RestorGenex Presents Results of Experimental Idiopathic Pulmonary Fibrosis Therapy
Idiopathic Pulmonary Fibrosis, News
RestorGenex, a biopharmaceutical company focused on developing a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space, recently announced that Nathan Sandbo, M.D. and ... Read more